Crizotinib versus alectinib for the treatment of ALK-positive non-small cell lung cancer: a systematic review and meta-analysis
Q Zeng, X Zhang, S He, Z Zhou, L Xia, W Zhang… - Chemotherapy, 2022 - karger.com
Background: Crizotinib and alectinib are the 2 most commonly used anaplastic lymphoma
kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared …
kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared …
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
JD Soumerai, A Rosenthal, S Harkins… - Blood, The Journal …, 2022 - ashpublications.org
COI notes: Jacob D. Soumerai reports consulting fees from Abbvie, AstraZeneca, Beigene,
Biogen, Bristol Myers Squibb, Roche, TG Therapeutics, and Verastem, and research funding …
Biogen, Bristol Myers Squibb, Roche, TG Therapeutics, and Verastem, and research funding …
Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
S Murakami, T Yokose, K Shinada, T Isaka… - Thoracic …, 2022 - Wiley Online Library
Background As the number of genetic mutations that must be tested increases, the
Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related …
Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related …
[HTML][HTML] Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly …
Background The number of randomized trials of agents targeting oncogene-addicted tumors
has surged in the past 10 years. Using a meta-analysis, we explored whether improvements …
has surged in the past 10 years. Using a meta-analysis, we explored whether improvements …
[HTML][HTML] Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study
Y Jiang, Y Shi, Y Liu, Z Wang, Y Ma, X Shi… - … lung cancer research, 2022 - ncbi.nlm.nih.gov
Background Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs),
which has attracted much attention in the treatment of ALK-positive non-small cell lung …
which has attracted much attention in the treatment of ALK-positive non-small cell lung …
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
Y Wang, S Shen, P Hu, D Geng, R Zheng… - Cancer Medicine, 2022 - Wiley Online Library
Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients
with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real …
with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real …
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
AP Jayan, KR Anandu, K Madhu, VN Saiprabha - Medical Oncology, 2022 - Springer
Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85%
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …
Clinically-meaningful improvements in therapy for unresectable NSCLC
S Katakura, S Murakami - Expert Review of Anticancer Therapy, 2022 - Taylor & Francis
Introduction The ideal management of patients with unresectable non-small-cell lung cancer
(NSCLC) is still developing. Unresectable NSCLC has a high mortality rate and poor …
(NSCLC) is still developing. Unresectable NSCLC has a high mortality rate and poor …
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
T Sakashita, N Yanagitani, S Koike, SK Low… - Cancer …, 2022 - Wiley Online Library
The rearrangement of anaplastic lymphoma kinase (ALK) occurs in 3%‐5% of patients with
non–small cell lung cancer (NSCLC) and confers sensitivity to ALK–tyrosine kinase …
non–small cell lung cancer (NSCLC) and confers sensitivity to ALK–tyrosine kinase …
Comparison of efficacy and safety of brigatinib in first-line treatments for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer: a systematic …
Y Yu, F Zhu, W Zhang, S Lu - Journal of Clinical Medicine, 2022 - mdpi.com
(1) Background: The relative efficacy and safety of brigatinib compared with other next-
generation anaplastic lymphoma kinase (ALK) inhibitors remains unclear, as first-line head …
generation anaplastic lymphoma kinase (ALK) inhibitors remains unclear, as first-line head …